Olympiad Research LP Sells 214 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Olympiad Research LP reduced its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 680 shares of the company’s stock after selling 214 shares during the period. Olympiad Research LP’s holdings in Medpace were worth $226,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. R Squared Ltd purchased a new position in Medpace during the 4th quarter worth $30,000. Stone House Investment Management LLC purchased a new position in Medpace during the 3rd quarter worth $33,000. Ashton Thomas Securities LLC purchased a new position in Medpace during the 3rd quarter worth $37,000. Capital Performance Advisors LLP purchased a new position in Medpace during the 3rd quarter worth $46,000. Finally, True Wealth Design LLC increased its holdings in Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Robert W. Baird lifted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus target price of $381.44.

Medpace Stock Down 1.2 %

Shares of MEDP stock opened at $340.78 on Monday. The stock has a market cap of $10.38 billion, a PE ratio of 26.98, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. The business has a 50-day simple moving average of $343.13 and a 200-day simple moving average of $346.97. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.